Novotech, the global full-service Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has announced the launch of a dedicated early phase unit focussed on leveraging the unique advantage of Australia and New Zealand (ANZ) for early phase clinical development.

This Early Phase Strategic Delivery Unit (EP SDU) is the first in a series of new Strategic Delivery Units (SDUs) to be launched by Novotech over the course of 2024, each one being a dedicated delivery unit with specialist teams and tailored processes, for different types of complex clinical trials.

Novotech has long been a partner of choice for biotechs wanting to conduct early phase trials in ANZ and benefit from the clinical and scientific excellence, attractive financial rebates, and rapid startup with streamlined regulatory processes.

Novotech CEO Dr John Moller said, “Our Early Phase Strategic Delivery Unit ensures that, as our global operations continue to grow, our commitment to excellence in Phase I delivery across ANZ remains a core and integral part of Novotech's service offering. This continues to serve as a platform for our biotech clients to expedite their early phase work before expanding into later phase global development with Novotech”.